CatalystFDA/Bio

Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy

FDA clearance of AP308's IND marks a regulatory milestone for IgA nephropathy treatment.

What changed

FDA clearance of AP308's IND marks a regulatory milestone for IgA nephropathy treatment.

Why it matters

FDA clearance of AP308's IND marks a regulatory milestone for IgA nephropathy treatment. — impact context not separately stored; see What changed.

Sources